2,117 reports of this reaction
4.2% of all AZACITIDINE reports
#3 most reported adverse reaction
ACUTE MYELOID LEUKAEMIA is the #3 most commonly reported adverse reaction for AZACITIDINE, manufactured by Celgene Corporation. There are 2,117 FDA adverse event reports linking AZACITIDINE to ACUTE MYELOID LEUKAEMIA. This represents approximately 4.2% of all 50,397 adverse event reports for this drug.
Patients taking AZACITIDINE who experience acute myeloid leukaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE MYELOID LEUKAEMIA is moderately reported among AZACITIDINE users, representing a notable but not dominant share of adverse events.
In addition to acute myeloid leukaemia, the following adverse reactions have been reported for AZACITIDINE:
The following drugs have also been linked to acute myeloid leukaemia in FDA adverse event reports:
ACUTE MYELOID LEUKAEMIA has been reported as an adverse event in 2,117 FDA reports for AZACITIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE MYELOID LEUKAEMIA accounts for approximately 4.2% of all adverse event reports for AZACITIDINE, making it one of the most commonly reported side effect.
If you experience acute myeloid leukaemia while taking AZACITIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.